Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	196.69M
Revenue (ttm)	79.20M
Net Income (ttm)	-133.82M
Shares Out	21.06M
EPS (ttm)	-6.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	663,928
Open	10.00
Previous Close	9.92
Day's Range	9.29 - 10.37
52-Week Range	8.08 - 62.06
Beta	0.48
Analysts	Buy
Price Target	37.63 (+302.89%)
Earnings Date	Nov 20, 2023

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the ma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTA

Financial Performance

In 2023, ENTA's revenue was $79.20 million, a decrease of -8.07% compared to the previous year's $86.16 million. Losses were -$133.82 million, 9.91% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is $37.63, which is an increase of 302.89% from the latest price.

Price Target

$37.63

(302.89% upside)

Analyst Consensus: Buy